NL-OMON30091尚未招募3 期
A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF alfa Chimeric Monoclonal Antibody (Infliximab, Remicade) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis. - Trial V
Medical University of Vienna AKH, Department of Rheumatology, Internal Medicine III, Josef Smolen, MD0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-SLE with biopsy-proven membranous glomerulonephritis (WHO class V)
- •-Proteinuria >3g/day despite adequate therapy with ACE inhibitors
- •-Individuals (>18 years) who have the capacity to understand and sign an informed consent
- •-No evidence of current active TB or old inactive TB
排除标准
- •-Active WHO class IV SLE nephritis
- •-Treatment with azathioprine / cyclophosphamide within the previous 12 months, or with cyclosporine within the previous 6 weeks
- •-Active cerebral SLE
- •-Active infection, malignancy
研究者
相似试验
招募中
3 期
Evaluate the Efficacy and Safety of Thymosin α-1 (Tα1) with comparision of placebo in sepsis patient by using with Standrad of careCTRI/2022/09/045538Gufic Biosciences Limited
进行中（未招募）
1 期
Study is to find out more about evolocumab in HIV-positive patient`s and with high cholesterol(hyperlipidemia and/or mixed dyslipidemia).HIV and hyperlipidemia or mixed dyslipidemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 23.0Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861MedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848EUCTR2015-004735-12-ITAMGEN INC.467
进行中（未招募）
1 期
Study is to find out more about evolocumab in HIV-positive patient`s and with high cholesterol (hyperlipidemia and/or mixed dyslipidemia).HIV and hyperlipidemia or mixed dyslipidemia.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 23.0Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848MedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2015-004735-12-PTAmgen Inc467
进行中（未招募）
1 期
Study is to find out more about evolocumab in HIV-positive patient`s and with high cholesterol (hyperlipidemia and/or mixed dyslipidemia).HIV and hyperlipidemia or mixed dyslipidemia.MedDRA version: 20.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 20.1Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848MedDRA version: 20.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2015-004735-12-FRAmgen Inc450
进行中（未招募）
不适用
A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisSystemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisEUCTR2005-004067-30-ATDepartment of Rheumatology, Internal Medicine III, Medical University of Vienna44